EVAX - Evaxion Biotech A/S Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

EVAX

EVAXION BIOTECH A/S

NASDAQ

$3.01

▼ DOWN 4.44% (-0.14)

KEY STATISTICS

Market Cap$19.01 M

52w High$12.15

52w Low$2.52

Dividend Yield—

Frequency—

P/E-2.05

Volume122.55K

Shares Out.6.32M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Helen Katrina Tayton-Martin

ABOUT

SECTOR

Healthcare

WENT PUBLIC

February 5, 2021

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$9.00

Target Low$9.00

Target Median$9.00

Target Consensus$9.00

UPCOMING EARNINGS

DateNov 5, 2026

DayThursday

Rev. Est.$300.00K

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2025-01-14	Reverse	1:5
2024-01-22	Reverse	1:10

PRICE

$3.01 ▼ DOWN 4.44% (−$0.14)

OVERLAYS

About Evaxion Biotech A/S

https://evaxion.ai ↗

Evaxion Biotech is a Denmark-based clinical-stage biotech developing AI-driven immunotherapies and vaccines for cancers, bacterial, and viral diseases, with several programs in clinical and preclinical stages.

INDUSTRY

Biotechnology

A PRODUCT EVAXION BIOTECH A/S IS KNOWN FOR

EVX-01

EVX-01 is a personalized AI-driven cancer vaccine in Phase 2 trials for melanoma, lung, and bladder cancers, designed to activate the immune system by targeting optimal cancer-specific antigens.